Kv1.3/Kv1.5 heteromeric channels compromise pharmacological responses in macrophages
- PMID: 17157812
- DOI: 10.1016/j.bbrc.2006.11.120
Kv1.3/Kv1.5 heteromeric channels compromise pharmacological responses in macrophages
Abstract
Voltage-dependent K(+) (Kv) channels are involved in the immune response. Kv1.3 is highly expressed in activated macrophages and T-effector memory cells of autoimmune disease patients. Macrophages are actively involved in T-cell activation by cytokine production and antigen presentation. However, unlike T-cells, macrophages express Kv1.5, which is resistant to Kv1.3-drugs. We demonstrate that mononuclear phagocytes express different Kv1.3/Kv1.5 ratios, leading to biophysically and pharmacologically distinct channels. Therefore, Kv1.3-based treatments to alter physiological responses, such as proliferation and activation, are impaired by Kv1.5 expression. The presence of Kv1.5 in the macrophagic lineage should be taken into account when designing Kv1.3-based therapies.
Similar articles
-
Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels.Biochem Pharmacol. 2010 Sep 15;80(6):858-66. doi: 10.1016/j.bcp.2010.05.012. Epub 2010 May 19. Biochem Pharmacol. 2010. PMID: 20488163
-
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.Mol Pharmacol. 1994 Jun;45(6):1227-34. Mol Pharmacol. 1994. PMID: 7517498
-
Association of Kv1.5 and Kv1.3 contributes to the major voltage-dependent K+ channel in macrophages.J Biol Chem. 2006 Dec 8;281(49):37675-85. doi: 10.1074/jbc.M605617200. Epub 2006 Oct 11. J Biol Chem. 2006. PMID: 17038323
-
Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.Expert Opin Ther Targets. 2009 Aug;13(8):909-24. doi: 10.1517/14728220903018957. Expert Opin Ther Targets. 2009. PMID: 19538097 Review.
-
Biophysical and pharmacological aspects of K+ channels in T lymphocytes.Eur Biophys J. 2005 Aug;34(6):515-29. doi: 10.1007/s00249-005-0499-3. Eur Biophys J. 2005. PMID: 16184309 Review.
Cited by
-
K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.Chem Rev. 2008 May;108(5):1744-73. doi: 10.1021/cr078234p. Chem Rev. 2008. PMID: 18476673 Free PMC article. Review. No abstract available.
-
Oligomerization and Spatial Distribution of Kvβ1.1 and Kvβ2.1 Regulatory Subunits.Front Physiol. 2022 Jun 17;13:930769. doi: 10.3389/fphys.2022.930769. eCollection 2022. Front Physiol. 2022. PMID: 35784882 Free PMC article.
-
Kv1.5 association modifies Kv1.3 traffic and membrane localization.J Biol Chem. 2008 Mar 28;283(13):8756-64. doi: 10.1074/jbc.M708223200. Epub 2008 Jan 24. J Biol Chem. 2008. PMID: 18218624 Free PMC article.
-
KCNE4-dependent functional consequences of Kv1.3-related leukocyte physiology.Sci Rep. 2021 Jul 16;11(1):14632. doi: 10.1038/s41598-021-94015-9. Sci Rep. 2021. PMID: 34272451 Free PMC article.
-
Electroimmunology and cardiac arrhythmia.Nat Rev Cardiol. 2021 Aug;18(8):547-564. doi: 10.1038/s41569-021-00520-9. Epub 2021 Mar 2. Nat Rev Cardiol. 2021. PMID: 33654273 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources